PRMT5 and systemic sclerosis: Patients with SSc who fulfilled the criteria of progressive fibrosing interstitial lung disease (ILD) (PF-ILD) in the subsequent 24-month follow-up demonstrated significantly increased basal levels of anti-PRMT5 antibodies compared with the patients with SSc without developing PF-ILD (figure 4G).